class=”sc-29f61514-0 icZBHN”>
Similasan has a problem in the US. And a really big one. The US Food and Drug Administration (FDA) imposed a de facto import ban on the Swiss homeopathy manufacturer; sales dropped 90 percent. Currently 12 products are blacklisted. This gets to the heart of the matter. After all, Similasan makes 50 percent of its sales in the United States.
This also has an impact on the headquarters at Jonen AG. Rumors of as many as 40 layoffs by the end of the month were circulating Friday. Similasan says they are in close contact with authorities in the United States and Switzerland. “We are also evaluating transition and alternative solutions. “We have applied for short-time work for employees responsible for the production of US products,” a spokesperson told Blick.
Various uncertainties
That’s not all: “Unfortunately, we also have to prepare for possible layoffs due to uncertainties regarding the duration and extent of sales loss in the American market,” he says.
These preparations and consultation processes are currently still formal, precautionary measures to be prepared for all eventualities. “In this extraordinarily challenging situation, we, together with our employees, are doing everything we can to clarify the situation and find a solution as quickly as possible,” he said.
A number of deficiencies were identified
In the spring, the Americans inspected the production facility in Jonen and discovered a number of defects in production. Especially with eye drops. The FDA’s accusations are harsh: Procedures to prevent drug contamination are inadequate. Laboratory and quality controls did not meet relevant standards. Additionally, many of the drugs sold are not approved.
CEO Urs Lehmann (54) emphasized: The safety and health of customers were never at risk. Similasan is not aware of any cases that question the safety of its medicines. Similasan has been operating in the US market since 1987 and has sold over 100 million eye drop packages during that period.
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
